Newsroom | 4256 results

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. “It has been a productive third quarter for the Lineage team,” stated Brian...

GURUGRAM, India--(BUSINESS WIRE)--Fortis Memorial Research Institute, Gurugram, reveals success in curing children with Sickle Cell Disease through Bone Marrow transplantation....

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Cash, cash equivalents, and marketable securities: As of September 30, 2025, Arcellx had cash, cash equivalents, and marketable securities of $576.0 mi...

MINNEAPOLIS--(BUSINESS WIRE)--NMDPSM, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®), will present groundbreaking research at the 67th American Society of Hematology (ASH) Annual Meeting from Dec. 6-9 in Orlando, Fla. The data underscore NMDP’s commitment to advancing cell therapy and improving access and outcomes for all patients. Among the accepted abstracts is an oral presentation from the ACCESS clinical trial (NCT0490...

GERMANTOWN, Md.--(BUSINESS WIRE)--Amarex today announced its partnership with Britecyte, the Maryland Stem Cell Research Fund (MSCRF) $1M clinical grant awardee, to support the development of Britecyte’s Adipose Tissue Allograft (BRC-OA) for the treatment of osteoarthritis (OA), a serious and debilitating disease with unmet needs. Britecyte is collaborating with Amarex and Regenerative Orthopedics & Sports Medicine (ROSM) to determine the safety and efficacy of the BRC-OA treatment, which h...

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced new preclinical data demonstrating proof-of-concept for its in vivo, HSC-derived CAR-M, NK, and T cell platform, including its potential to durably generate lineage-restricted CAR cells in solid tumors. The data will be presented in two poster sessions this week at the Society for Immunotherapy of Cancer (SITC)...

LAS VEGAS--(BUSINESS WIRE)--Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), a Nevada-based corporation, and SGAustria Pte. Ltd. (SGAustria), a Singapore-based biotechnology company, today announced the formation of a groundbreaking Joint Venture and License Agreement aimed at revolutionizing a diabetes treatment through innovative stem cell and encapsulation technologies. The Joint Venture will now pursue a Research Collaboration Agreement (RCA) to advance a proprietary differ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced it will share two presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2025, in Orlando, Florida, including updated clinical data from iMMagine-1, its Phase 2 pivotal study (publication #25...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio announces new clinical data on its high-precision cell therapies will be presented at the 67th American Society of Hematology Annual Meeting...

加利福尼亚州埃默里维尔--(BUSINESS WIRE)--(美国商业资讯)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA)（"Estrella"或"公司"）是一家临床阶段生物制药公司，致力于开发靶向CD19和CD22的ARTEMIS® T细胞疗法以治疗癌症和自身免疫性疾病。公司今日宣布，其用于治疗晚期B细胞非霍奇金淋巴瘤（NHL）的CD19靶向ARTEMIS® T细胞疗法EB103已经顺利完成STARLIGHT-1 I/II期临床试验的I期剂量爬坡阶段的第二剂量组。 关键发现： 在该研究第二剂量组中，所有可评估患者在治疗第1个月时均达到完全缓解（CR），完全缓解率为100%。 所有接受治疗的患者均为不适合接受商业化CD19产品治疗的高风险人群，其中包括一名中枢神经系统（CNS）淋巴瘤患者。在本研究阶段，未发生任何与治疗相关的严重不良事件（SAE）。 "第二剂量组以100%的完全缓解率完成，这是我们EB103临床项目中的一个重要里程碑，" Estrella 首席执行官刘诚博士表示。"在这一高风险受试群体（包括一名中枢神经系统淋巴瘤患者）中观察到...